NASDAQ · KLRS
Kalaris Therapeutics Inc
Healthcare · Biotechnology
$2.23▼ 1.33% ($0.03)at close
After hours$2.30▲ 3.14%5:38 PM ET
Market cap
$48.68M
P/E
N/M
EPS (TTM)
-$1.86
Next earnings
Nov 11, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
Data notes
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $2.23 · Price Oct 13, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 53.15% over the last year.
What the market seems to be pricing
The stock has moved lower with no clear directional signal from operating metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
A decisive shift in revenue or free cash flow over the next period would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases.
Market multiples
Stock splits
Every 23 shares became 1
Profitability & growth
Analyst consensus
1
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 11, 2026
Q3 FY26 · EPS est -$0.52 · Revenue est —
Q2 FY26
Reported Aug 11, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$0.48
Estimate
-$0.50
Year over year
n/m
Vs prior quarter
n/m
4 beats in the last 4 quarters
Institutional Sentiment
Kalaris Therapeutics Inc · KLRS
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.